A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm

[1]  D. Follmann,et al.  A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia , 2020, The New England journal of medicine.

[2]  T. Bhatnagar,et al.  Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) , 2020, BMJ.

[3]  M. Salesi,et al.  Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study , 2020, Transfusion and Apheresis Science.

[4]  T. Wengenmayer,et al.  Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation , 2020, Critical Care.

[5]  E. Wood,et al.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. , 2020, The Cochrane database of systematic reviews.

[6]  Zhenghao Xu,et al.  Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies , 2020, Frontiers in Immunology.

[7]  M. M. van der Eerden,et al.  Convalescent Plasma for COVID-19. A randomized clinical trial , 2020, medRxiv.

[8]  Qianghu Wang,et al.  Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion , 2020, Blood.

[9]  J. Pagel,et al.  Use of convalescent plasma in hospitalized patients with COVID-19: case series , 2020, Blood.

[10]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[11]  S. W. Long,et al.  Treatment of COVID-19 Patients with Convalescent Plasma , 2020, The American Journal of Pathology.

[12]  Giuseppe Magro.  Cytokine Storm: Is it the only major death factor in COVID-19 patients? Coagulation role , 2020, Medical Hypotheses.

[13]  H. Ducou le Pointe,et al.  Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome , 2020, American journal of hematology.

[14]  Xiaowei Yan,et al.  Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 , 2020, The New England journal of medicine.

[15]  Yan Peng,et al.  Effectiveness of convalescent plasma therapy in severe COVID-19 patients , 2020, Proceedings of the National Academy of Sciences.

[16]  Hui Guo,et al.  First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab , 2020, Blood Advances.

[17]  N. Chaput,et al.  Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report , 2020, Annals of Oncology.

[18]  J. Lenzer.  Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence , 2020, BMJ.

[19]  Rui-guang Zhang,et al.  Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[21]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[22]  L. Chen,et al.  [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[23]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[24]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[25]  R. Liu,et al.  Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors , 2020, Emerging microbes & infections.

[26]  N. Chaput,et al.  Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report , 2020 .

[27]  Qin Ning,et al.  Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .

[28]  J. Anaya,et al.  Ebola virus disease: An emerging and re-emerging viral threat. , 2019, Journal of autoimmunity.

[29]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[30]  Lifei Hou,et al.  Immune suppressive properties of artemisinin family drugs. , 2016, Pharmacology & therapeutics.

[31]  B. Pozzetto,et al.  Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow , 2016, Transfusion Clinique et Biologique.

[32]  J. Lünemann,et al.  Intravenous immunoglobulin in neurology—mode of action and clinical efficacy , 2015, Nature Reviews Neurology.

[33]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[34]  K. Yuen,et al.  Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. , 2013, Chest.

[35]  R. Benjamin,et al.  Plasma components: properties, differences, and uses , 2012, Transfusion.

[36]  Kwok-Hung Chan,et al.  Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  J. Modrof,et al.  West Nile virus neutralization by US plasma-derived immunoglobulin products. , 2007, The Journal of infectious diseases.